Cell Cycle Arrest Biomarkers: New Weapons for A New Battle

Ronco, Claudio

doi:10.1159/000375470

Cited by 7 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Advances in this field have been made with the discovery and validation of cell-cycle arrest biomarkers, such as tissue inhibitor of metalloproteinase 2 and insulin-like growth factor binding protein 7 [36]. The combination of these biomarkers, which was measured by the approved NephroCheck test [36], appears to be highly predictive of the risk of moderate to severe AKI in the subsequent 24-48 h [37]. However, the NephroCheck test has not yet been validated as a prognostic test for CI-AKI.…”

Section: Statement 6 the Combination Of Markers Of Functional Damage mentioning

confidence: 99%

Methods to Address Computed Tomography-Related Risk Factors in Oncology Patients: An Expert Opinion Based on Current Evidence

2018

Self Cite

View full text Add to dashboard Cite

Background: The present paper is intended to be a practical guide organized by statements describing methods to reduce risks related to CT examinations in cancer patients. Methods: A panel of radiologists, oncologists and nephrologists were selected based on their publication records in the field and expertise. Ten clinical questions, which were derived from clinical needs and an integration of all the committee members’ suggestions, were stated. The modified Delphi approach was used; it involved a detailed literature review and the collective judgement of experts, including electronic and face-to-face discussions. Results: Ten statements were derived from expert opinions based on the current literature, recently developed guidelines and technological advancements. Each statement is discussed in a short paragraph reporting the current key evidence. Conclusion: This paper addresses the clinical implications of performing numerous CT examinations in patients with cancer, providing clinicians with information regarding methods to reduce risk factors in this patient population.

show abstract

Section: Statement 6 the Combination Of Markers Of Functional Damage mentioning

confidence: 99%

Methods to Address Computed Tomography-Related Risk Factors in Oncology Patients: An Expert Opinion Based on Current Evidence

2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…TIMP-2 and IGFBP7 are G1 cell cycle arrest markers that are upregulated early after AKI onset and have also been proposed to have a renoprotective role. However, the observation that a prolonged cell cycle arrest results in maladaptive repair led us to hypothesize that a prolonged upregulation of these markers might represent the development or progression of CKD following AKI [7,8].…”

Section: Introductionmentioning

confidence: 99%

Urinary tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 as biomarkers of patients with established acute kidney injury

Cho

Lim

Yang

et al. 2020

Korean J Intern Med

View full text Add to dashboard Cite

Background/Aims: Urinary tissue inhibitor of metalloproteinase-2 (TIMP-2) and insulin-like growth factor-binding protein 7 (IGFBP7) have been recently discovered and validated as sensitive biomarkers that can predict stage 2 or 3 acute kidney injury (AKI) development in high-risk patients. We aimed to assess whether these biomarkers could predict adverse outcomes and renal recovery in established AKI patients. Methods: This was a single-center study prospectively enrolling 124 patients diagnosed with AKI. TIMP-2, IGFBP7, neutrophil gelatinase-associated lipocalin (NGAL), and kidney injury molecule 1 (KIM-1) levels were measured at the time of diagnosis and the predictive performance of short-term outcomes and renal recovery was assessed. Results: Patients were divided into 4 quartiles according to the initial urinary TIMP-2/IGFBP7 levels. Stage 3 AKI (odds ratio [OR], 17.86), classified by the Kidney Disease Improving Global Outcomes (KDIGO), as well as the third and fourth quartiles of TIMP-2/IGFBP7 (OR, 5.75 and 44.98, respectively), were found to be independent predictors of renal replacement therapy at the time of AKI diagnosis. In addition, KDIGO stage 3 AKI (OR, 2.468) or the third of fourth quartiles of urinary TIMP-2/IGFBP7 (OR, 1.896 and 3.622, respectively) were also found to be useful in predicting nonrecovery of renal function. In a separate analysis of patients with renal recovery at discharge, initial urinary TIMP-2/IGFBP7 or urinary IGFBP7 at discharge could also predict new-onset or progressive chronic kidney disease (CKD). Conclusions: In AKI patients, urine TIMP-2/IGFBP7 could serve as a biomarker for predicting adverse outcomes, renal recovery, or the development and progression of CKD.

show abstract

“…[ 9 ] However, none of these potential markers has been widely used in clinical practice because they do not exhibit acceptable accuracy for the early diagnosis of kidney injury and the early identification of at-risk patients. [ 10 ]…”

Section: Introductionmentioning

confidence: 99%

The diagnostic accuracy of urinary [TIMP-2]·[IGFBP7] for acute kidney injury in adults

Liu

Mao

et al. 2017

Medicine

View full text Add to dashboard Cite

Introduction:Early diagnosis of acute kidney injury (AKI) remains a challenge. Recently, [TIMP-2]·[IGFBP7], which is a combination of urine tissue inhibitor of metalloproteinase 2 (TIMP-2) and insulin-like growth factor (IGF) binding protein 7 (IGFBP7), has been identified as a potential biomarker of AKI. We performed this meta-analysis to assess the diagnostic accuracy of urinary [TIMP-2]·[IGFBP7] for AKI in adult patients.Methods:We searched the PubMed, Embase, and Cochrane Library databases from database inception to March 2017. Two authors independently screened articles based on inclusion and exclusion criteria and assessed the methodological quality of each included study using the Quality Assessment of Diagnostic Accuracy Studies 2 criteria. Review Manager and STATA were used for all statistical analyses.Results:Nine studies (n = 1886) satisfied the inclusion criteria. Pooled analyses demonstrated that urinary [TIMP-2]·[IGFBP7] exhibited fair diagnostic accuracy for AKI (sensitivity [SEN] 0.83 [95% CI 0.75–0.89], specificity [SPE] 0.72 [95% CI 0.56–0.84], and area under the summary receiver operating characteristic [SROC] curve 0.86 [95% CI 0.82–0.88]) and AKI stage ≥ 2 (according to the 2012 Kidney Disease: Improving Global Outcomes [KDIGO] 2012 classification system; SEN 0.92 [95% CI 0.81–0.96], SPE 0.63 [95% CI 0.49–0.74], and area under the SROC curve 0.88 [95% CI 0.85–0.91]) in adult patients.Conclusion:Our findings indicate that urinary [TIMP-2]·[IGFBP7] may be a reliable biomarker for the early detection of AKI. However, given the significant heterogeneity among the included studies, clinicians should be aware of the utility and limitations of this biomarker in clinical practice. Additional high-quality studies examining a larger sample of patients are required.

show abstract

Cell Cycle Arrest Biomarkers: New Weapons for A New Battle

Cited by 7 publications

References 11 publications

Methods to Address Computed Tomography-Related Risk Factors in Oncology Patients: An Expert Opinion Based on Current Evidence

Methods to Address Computed Tomography-Related Risk Factors in Oncology Patients: An Expert Opinion Based on Current Evidence

Urinary tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 as biomarkers of patients with established acute kidney injury

The diagnostic accuracy of urinary [TIMP-2]·[IGFBP7] for acute kidney injury in adults

Contact Info

Product

Resources

About